Are you an Ozempic user, or considering starting on the drug? You may want to read this. Recent research is cause for concern, suggesting a potential link between Ozempic and a serious eye condition that can lead to sudden blindness. This study suggests that the active ingredient in the drug, semaglutide, can potentially cause non-arteritic anterior ischemic optic neuropathy (NAION). Scientists say that the risk is low, however, the findings have raised important questions regarding the safety and potential side effects of this diabetes and weight loss drug.
Ozempic: What You Should Know

Ozempic is a diabetes drug that contains the active ingredient semaglutide. It has also recently become quite popular for its efficacy in promoting weight loss. Marketed as a promising solution for individuals struggling with obesity, Ozempic has seen a huge spike in prescriptions and usage. This has drawn attention to possible unforeseen side effects associated with semalglutide.
What is non-arteritic anterior ischemic optic neuropathy?

NAION is a very serious eye condition. It is characterized by a sudden loss of vision due to the interruption of blood flow to the optic nerve. There are a variety of things that can increase your risk for developing NAOIN. One of these, as you can imagine, are certain medications, with the active ingredient in Ozempic being one of the most recently discovered potential triggers. It is a rare but serious condition can lead to permanent vision loss.
Ozempic and NAION: The Study

This lastest research was conducted in Denmark and Norway. The scientists sought to investigate the potential association between semaglutide and NAION. The study analyzed data from a large group of individuals who were eligible for semaglutide for the management of type 2 diabetes. Their results revealed concerning findings regarding the potential risk of developing NAION while on the drug. It is important to note that they did not include patients using Ozempic for weightloss only, and not diabetes management.
The Findings

The researchers found that among those using semaglutide, there was an increased incidence of NAION as compared to the general population. Their results show that for every 10,000 people on a semaglutide-containing drug, one additional person could develop NAION within one year. While this absolute risk is still considered low, it is not zero and still considered statistically significant. The findings raise important questions about the safety profile of this active ingredient.
“Although there are some interesting studies on the topic, it is premature to conclude that the association between semaglutide and NAION is a causal association,” Andrew Lee, MD, spokesperson for the American Academy of Ophthalmology and a neuro-ophthalmologist at Houston Methodist Hospital, told Health.
What this means for Ozempic Users

All of that being said, experts are still cautioning against jumping to conclusions. They emphasize that the overall risk of developing NAION continues to appear to be very low. This is irrespective of semaglitude use. Individuals currently using Ozempic or considering its use should consult with their healthcare providers about the potential risks and benefits specific to their individual health and needs. As always, if weight loss can be achieved without medication intervention, this is always the preferred and lowest-risk route to health.
“That study is seemingly well conducted,” Dr. Anton Pottegård said, “but it is using a dataset that is quite peculiar, in that they only have data from patients that at some point had a contact to a specialist ophthalmologist [or neuro-ophthalmologist], which renders it quite difficult to draw conclusions from.”
Is Ozempic right for you?

The decision to use Ozempic is an individual one and therefore should be taken on a case-by-case basis. All pros and cons for each person considering the drug should be carefully weighed in consultation with a medical doctor who understands the risks and potentially benefits, as well as that persons individual health profile. Though this study does raise some concerns, it is important for individuals to consider their personal risk factors. They should have an informed discussion with their healthcare provider before starting or continuing treatment with Ozempic. This conversation will differ quite significantly depending on the reasons you have for considering the drug in the first place.
The Bottom

As health experts have been saying for decades, there is no magic pill to weight loss. This includes Ozempic, as no matter what, life style changes will still be necessary for ultimate, long-term weight loss success. As more research on this link between semaglutide and NAION is done, it is essential for individuals to remain informed and in constant communication with their medical team about their individual risk. The decision to use Ozempic should be made in conjunction with healthcare providers and should consider the potential benefits and risks specific to each individual. If you don’t feel your doctor is listening to your concerns, or if you feel that they are trying to push anything on you that you are unsure of, seek out a second opinion. The study emphasizes the importance of continued research in monitoring the safety of all medications to ensure the well-being of their users, as well as the importance of the general public to be informed of the risks of all medications that they are taking.
Read More: Ozempic May Pose a Risk for Cancer Patients During Treatment, Study Shows